ACoP14 2023

Workshop: Pre-Meeting Workshop (8 am – 5 pm ET) – Model-Based Meta-Analysis (MBMA): Concepts, Methodologies, and Hands-on Workshop.

Workshop: Pre-Meeting Workshop (8 am – 5 pm ET) – Simcyp Designer PBPK-QSP Focused Workshop

Demo: QSP/Simcyp Designer: A graphical editor to seamlessly integrate QSP models with Simcyp Simulator

Concurrent Session 1B – Moving Boundaries: Towards Virtual Twin Patients in Clinical Trials and Precision Medicine for CNS Disorders.

Concurrent Session 1B – MIDD V2.0: Integrating Mechanistic Modeling and Artificial Intelligence.

Demo: PMX Pharmacometrics Tools: Tailored for all user levels. Explore our new machine learning model selection feature in Pirana, along with advanced R, Shiny, and R Markdown reporting.

Demo: QSP Designer/Neuro: Platform offering a powerful tool to predict the effect of amyloid antibodies on biomarkers and side-effects in a clinical Alzheimer population in both trial design and real-world treatment.

Demo: CODEX Analytics App: Software to enable intuitive exploration and analyses of clinical outcomes databases

Demo: PMX Pharmacometrics Tools: Tailored for all user levels. Explore our new machine learning model selection feature in Pirana, along with advanced R, Shiny, and R Markdown reporting.

Demo: PMX Pharmacometrics Tools: Tailored for all user levels. Explore our new machine learning model selection feature in Pirana, along with advanced R, Shiny, and R Markdown reporting.

Demo: QSP Model of Complement System (CS): Complement pathway in immune defense.

IsoP Trainee Communication Challenge

Poster Presentation: Dose Guidance for a Novel Combination Therapy to Treat Head and Neck Squamous Cell Carcinoma (HNSCC) for Patients with HRAS/PIK3CA Variants Using a Quantitative Systems Pharmacology (QSP) Model

Poster Presentation: Exploring treatment guidelines for amyloid therapies in Alzheimer’s Disease Using Predictive Quantitative System Pharmacology Modeling

Poster Presentation: A population-based approach predicts COVID-19 paediatric immunobridging trial outcomes using a QSP model of Tozinameran mRNA vaccine

Population Pharmacokinetic Modeling of Dordaviprone in Healthy Adult Participants and Adult and Pediatric Patients with Solid Tumors.

Evaluation of the Boruta Machine Learning Algorithm for Covariate Selection

Co-Sponsor International Masquerade Social Event

Demo: QSP/Simcyp Designer: A graphical editor to seamlessly integrate QSP models with Simcyp Simulator.

Demo: PMX Pharmacometrics Tools: Tailored for all user levels. Explore our new machine learning model selection feature in Pirana, along with advanced R, Shiny, and R Markdown reporting.

Demo: QSP/Simcyp Designer: A graphical editor to seamlessly integrate QSP models with Simcyp Simulator.

Demo: Vachette – Discover a new and innovative method for visualizing and communicating models with covariate effects made available within the ‘vachette’ R package.

Session: Application of PBPK model in predicting TP-DI with cytokine modulators

Demo: PMX Pharmacometrics Tools: Tailored for all user levels. Explore our new machine learning model selection feature in Pirana, along with advanced R, Shiny, and R Markdown reporting.

Session: Predicting Disease Activity Scores in Inflammatory Bowel Disease by Connecting Simulated Tissue Biomarkers of a Virtual Population to Clinical Biomarkers and Outcomes Using a Novel Algorithm

Session: Roller Coaster 1

Demo: QSP model of Irritable Bowel Disease (IBD): Auto-immune disease of digestive track.

Poster Presentation: The interaction of core modules as a basis for elucidating network behavior determining Parkinson’s disease pathogenesis

Poster Presentation: Predicting the impact of Haemodialysis with Simcyp Designer

Poster Presentation: A Quantitative Systems Pharmacology (QSP) Model to Investigate the Efficacy of a Novel Enzyme Replacement Therapy for Classical Homocystinuria (HCU)

Poster Presentation: NPSA: Nonparametric Simulated Annealing for Global Optimization

Population Pharmacokinetics Analysis of Bardoxolone Methyl in Healthy Subjects and Subjects with Chronic Kidney Diseases.

Pharmacometric Model to Describe the Relationship between Bardoxolone Methyl Exposure and eGFR Changes in Patients with Chronic Kidney Disease at Risk of Rapid Progression.